Giritharan S, et al. – Researchers present on the prevalence of growth hormone deficiency (GHD) in a large cohort of patients following subarachnoid haemorrhage (SAH), when dynamic and confirmatory pituitary hormone testing methods are systematically employed. Applying the recent testing protocol, the prevalence of GHD detected in this cohort was 14%. It is unclear if the body mass index (BMI) and waist hip ratio (WHR) difference found is truly due to GHD or confounded by the endocrine tests used in this protocol. There is possibly a correlation between the development of GHD and worse GOS score. Routine endocrine screening of all subarachnoid haemorrhage survivors with dynamic tests is time consuming and may subject many patients to unnecessary side–effects. The degree of clinical benefit derived from growth hormone replacement in this patient group, remains unclear. Moreover, increased understanding of the most appropriate testing methodology in this patient group and more importantly which SAH survivors would derive most benefit from GHD screening is required.